Approved by CDSCO, Mounjaro offers a breakthrough treatment for obesity and type 2 diabetes, helping millions manage weight and blood sugar with a once-weekly injection.
March 20, 2025: Eli Lilly and Company (India) has launched Mounjaro, a once-weekly injectable drug designed for weight loss and type 2 diabetes management. The drug, which has received marketing authorization from the Central Drugs Standard Control Organisation (CDSCO), is now available in a single-dose vial presentation.
Mounjaro is a first-of-its-kind treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors, making it an effective tool in managing obesity and diabetes.
Also Read: Pak Journalist Vs Cop Argument In English Sparks Internet Laughter – Watch Viral Video
Who Can Use Mounjaro?
The drug is recommended as an adjunct to a reduced-calorie diet and increased physical activity for:
- Adults with obesity (BMI ≥30 kg/m²)
- Overweight adults (BMI ≥27 kg/m²) with at least one weight-related comorbidity (such as high blood pressure, heart disease, or sleep apnea).
- Individuals with type 2 diabetes to improve glycemic control.
Why Is Mounjaro Important for India?
Also Read: ‘I Regret Moving to Canada’: Indian Student’s Viral Post Sparks Debate on Life Abroad
India faces a growing dual burden of obesity and diabetes:
- 101 million people in India have diabetes, and nearly half suffer from poor glycemic control.
- 100 million people in India are obese, with adult obesity rates reaching 6.5% in 2023.
- Obesity is linked to over 200 health complications, including hypertension, heart disease, and sleep apnea.
How Does Mounjaro Work?
Mounjaro is a prescription-based weekly injection that selectively binds to and activates both GIP and GLP-1 receptors. These incretin hormones help regulate:
✅ Appetite and weight loss
✅ Blood sugar levels
✅ Metabolism and energy balance
Eli Lilly’s Commitment to Public Health
“Obesity and type 2 diabetes are major health challenges in India. Lilly is committed to working with the government and industry to promote awareness and improve the prevention and management of these diseases,” said Winselow Tucker, President and General Manager, Eli Lilly India.
With Mounjaro’s once-a-week administration, patients now have a simpler and more effective treatment option to tackle weight loss and diabetes management.
Tags:
Eli Lilly India, Mounjaro India, Weight Loss Drug, Obesity Treatment, Type 2 Diabetes, CDSCO Approval, Indian Healthcare, GIP GLP-1, Diabetes Management, Prescription Medicine